Indications for Singulair® Expand with FDA Approval for Perennial Allergic Rhinitis
Sun, 21 Aug 2005 11:00 PM EST
... Merck & Co, Inc announced today that the US Food and Drug Administration (FDA) has approved SINGULAIR® (montelukast sodium) for the relief of symptoms of perennial allergic rhinitis (PAR), or indoor allergies, in adults and children six months of age and older... click link for more info. ...
Related Topics
- Allergic rhinitis
- Rhinitis
- Vaccine Testing & Approval
- Tacrolimus ointment
- Aspergillosis
- Mammography
- Carcinogens
- Allergic Reaction, Anaphylaxis
- Allergic Reaction, Angioedema
- Tarceva
- Pimecrolimus Cream 1%
- Dietary Guidelines
- Thalidomide
- Cefprozil
- Ceftriaxone Sodium Injection
- Food Labeling
- Sucralfate
- Hay Fever
- Mosquito Bites
- Conjunctivitis

Not Signed In -


